GAS6 and leukemia: Based on previous studies indicating a prognostic role for Gas6 in AML, we hypothesize that paracrine or autocrine expression of Gas6 (or other Mer ligands) by the leukemia cell itself or by the supportive marrow stroma [29, 33], could serve as a clinical biomarker, however further investigation is needed.